These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24839275)

  • 1. Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations.
    Kreys ED; Kim TY; Delgado A; Koeller JM
    J Oncol Pract; 2014 May; 10(3):168-73. PubMed ID: 24839275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergency room visits and hospital admission rates after curative chemotherapy for breast cancer.
    Pittman NM; Hopman WM; Mates M
    J Oncol Pract; 2015 Mar; 11(2):120-5. PubMed ID: 25585617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
    Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual patient and caregiver burden of oncology clinic visits for granulocyte-colony stimulating factor therapy in the US.
    Stephens JM; Li X; Reiner M; Tzivelekis S
    J Med Econ; 2016; 19(5):537-47. PubMed ID: 26745764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.
    Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R
    J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
    Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
    J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variables associated with emergency department and/or unplanned hospital utilization for children with epilepsy.
    Patel AD
    Epilepsy Behav; 2014 Feb; 31():172-5. PubMed ID: 24434308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.
    Rajan SS; Lyman GH; Stearns SC; Carpenter WR
    Med Care; 2011 Jul; 49(7):649-57. PubMed ID: 21478779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-Related Complications of Systemic Therapy and Radiotherapy.
    Jairam V; Lee V; Park HS; Thomas CR; Melnick ER; Gross CP; Presley CJ; Adelson KB; Yu JB
    JAMA Oncol; 2019 Jul; 5(7):1028-1035. PubMed ID: 30946433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
    Bradley AM; Deal AM; Buie LW; van Deventer H
    Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective.
    Kreys ED; Koeller JM
    J Oncol Pract; 2013 Sep; 9(5):e241-7. PubMed ID: 23943896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors.
    Johnson P; Bancroft T; Barron R; Legg J; Li X; Watson H; Naeim A; Watkins A; Marshall DA
    Value Health; 2014 Jun; 17(4):380-9. PubMed ID: 24968998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
    Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
    Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
    McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
    Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
    Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
    Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.